20 June 2022: Clinical Research
A Single-Center Retrospective Study to Compare the Efficacy and Safety of Modified FOLFIRINOX with S-1 as Adjuvant Chemotherapy in 71 Patients with Resected Pancreatic Carcinoma
Linhua Yao 1ABCEF , Chengwu Tang 2ABCEF , Wenming Feng 2ABFG , Hanbin Dai 2ABCE*DOI: 10.12659/MSM.937136
Med Sci Monit 2022; 28:e937136
Table 1 Patient characteristics.
| mFFX group (n=34) | S-1 group (n=37) | P value | |
|---|---|---|---|
| Age (year) | 55.47±6.75 | 56.27±6.93 | 0.6243 |
| Time from surgery to initiation of adjuvant chemotherapy (day) | 22.35±4.28 | 21.87±4.14 | 0.6326 |
| Postoperative CA19-9 (U/mL) | 30.85±9.18 | 31.29±9.85 | 0.8466 |
| WHO performance-status score | 0.9889 | ||
| 0 | 22 | 24 | |
| 1 | 12 | 13 | |
| Gender | 0.6091 | ||
| Male | 21 | 25 | |
| Female | 13 | 12 | |
| T Stage | 0.9172 | ||
| T1 | 10 | 11 | |
| T2 | 15 | 16 | |
| T3 | 6 | 5 | |
| T4 | 3 | 5 | |
| N Stage | 0.4924 | ||
| N0 | 12 | 10 | |
| N1 | 18 | 22 | |
| N2 | 4 | 5 | |
| Tumor stage | 0.5742 | ||
| I | 8 | 7 | |
| II | 20 | 22 | |
| III | 6 | 8 | |
| Tumor differentiation | 0.5057 | ||
| Well | 5 | 6 | |
| Moderately | 9 | 12 | |
| Poorly | 18 | 18 | |
| Unknown | 2 | 1 | |
| Operative procedure | 0.7833 | ||
| Pancreatoduodenectomy | 24 | 25 | |
| Distal pancreatectomy | 10 | 12 | |
| Histological type | 0.7499 | ||
| Ductal adenocarcinoma | 32 | 33 | |
| Nonductal carcinoma | 2 | 4 | |
| Comorbidities | |||
| Cardiovascular disease | 4 | 5 | 0.8920 |
| Respiratory disease | 7 | 8 | 0.8537 |
| Diabetes | 6 | 8 | 0.9029 |
| WHO – World Health Organization. | |||